Post Marketing Surveillance of JARDIANCE in Chronic Kidney Disease

Last updated: November 20, 2024
Sponsor: Boehringer Ingelheim
Overall Status: Active - Recruiting

Phase

N/A

Condition

N/A

Treatment

JARDIANCE®

Clinical Study ID

NCT06527846
1245-0340
  • All Genders

Study Summary

Study objective is to investigate the safety and effectiveness of long-term daily use of JARDIANCE® Tablets in patients with chronic kidney disease under real-world use.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Patients with CKD who are prescribed JARDIANCE® Tablets for CKD according to thecurrent Japanese package insert and who provided written informed consent prior toenrolment in this study.

  • Patients who have never been treated with JARDIANCE® Tablets (including treatmentfor Type 2 diabetes mellitus (T2DM) and/or chronic heart failure (CHF)) beforeenrolment.

Exclusion

Exclusion Criteria:

  • None

Study Design

Total Participants: 1000
Treatment Group(s): 1
Primary Treatment: JARDIANCE®
Phase:
Study Start date:
October 22, 2024
Estimated Completion Date:
May 31, 2027

Connect with a study center

  • Nippon Boehringer Ingelheim Co., Ltd.

    Tokyo, 1416017
    Japan

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.